About Vasculin
Vasculin (GPBP1) is a protein
from Homo sapiens identified by UniProt accession
Q86WP2, 473 residues long.
MolForge cross-references it against 0 known binders and
69 disease associations.
Target properties
| Protein name | Vasculin |
|---|
| UniProt accession | Q86WP2 |
|---|
| Gene | GPBP1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 473 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (69)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.33
- diastolic blood pressure · score 0.24
- asparaginase hypersensitivity · score 0.21
- adolescent idiopathic scoliosis · score 0.12
- total cholesterol measurement · score 0.12
- peak expiratory flow · score 0.12
- self reported educational attainment · score 0.08
- intelligence · score 0.06
- schizophrenia · score 0.06
- hypertrophic cardiomyopathy · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86WP2-F1 | alphafold | PREDICTED | 54.03 | — |
Amino-acid sequence (473 residues)
MAQHDFAPAW LNFPTPPSST KSSLNFEKHS ENFAWTENRY DVNRRRHNSS DGFDSAIGRP NGGNFGRKEK NGWRTHGRNG TENINHRGGY HGGSSRSRSS IFHAGKSQGL HENNIPDNET GRKEDKRERK QFEAEDFPSL NPEYEREPNH NKSLAAGVWE YPPNPKSRAP RMLVIKKGNT KDLQLSGFPV VGNLPSQPVK NGTGPSVYKG LVPKPAAPPT KPTQWKSQTK ENKVGTSFPH ESTFGVGNFN AFKSTAKNFS PSTNSVKECN RSNSSSPVDK LNQQPRLTKL TRMRTDKKSE FLKALKRDRV EEEHEDESRA GSEKDDDSFN LHNSNSTHQE RDINRNFDEN EIPQENGNAS VISQQIIRSS TFPQTDVLSS SLEAEHRLLK EMGWQEDSEN DETCAPLTED EMREFQVISE QLQKNGLRKN GILKNGLICD FKFGPWKNST FKPTTENDDT ETSSSDTSDD DDV
Explore Vasculin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets